Location: Barcelona, Spain
Date: September 16 to September 20
European Association for the Study of Diabetes.
Highlights of the 2019 EASD Congress
David R. Matthews, President of EASD explains the EASD statement on the new guidelines and summarize the highlights of the congress.
DAPA HF: The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial
The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF.
Early intervention with oral semaglutide and long term safety
Prof. Melanie Davies speaks about the two torchbearers in cardiovascular protection in diabetes, the SGLT2 inhibitors and GLP-1 analogs.
VERIFY and CONCLUDE study
Prof. Stefano Del Prato summarize the new findings of the VERIFY and CONCLUDE studies.
Cardiorenal risk in type 2 diabetes
Prof. Tina Vilsbøll discusses the current opinion about cardiorenal risk in patients with T2D.
Clinical properties and differences between GLP-1 agonists
Michael A. Nauck speaks about on the combinations of DPP4 inhibitors and SGLT2 inhibitors.
Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes
Prof. Hertzel Gerstein speaks about the question of the importance of glycemic control in the management of type 2 diabetes.
Diabetic retinopathy: Is the eye a mirror of the brain?
Prof. Coen D. A. Stehouwer speaks about the connection between diabetic retinopathy and other complications of diabetes.